CC-16 as a biomarker in chronic obstructive pulmonary disease

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 5, 2012, Pages 574-575

  Dickens, Jennifer A ^a   Lomas, David A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLARA CELL PROTEIN; CLARA CELL SECRETORY PROTEIN 16; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; SPUTUM LEVEL;

BIOLOGICAL MARKERS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UTEROGLOBIN;

EID: 84867078056     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.718926     Document Type: Article

References (19)

1. Umland TC et al., Structure of a human Clara cell phospholipidbinding protein-ligand complex at 1.9 A resolution. Nature structural biology 1994; 1(8):p.538-45.
2. Yoneda K, Ultrastructural localization of phospholipases in the Clara cell of the rat bronchiole. The American journal of pathology 1978; 93(3):p.745-52.
3. Van Vyve T et al., Protein content in bronchoalveolar lavage fl uid of patients with asthma and control subjects. The Journal of allergy and clinical immunology 1995; 95(1 Pt 1):p.60-8.
4. Benson, M., et al., Gene profi ling reveals decreased expression of uteroglobin and other anti-infl ammatory genes in nasal fl uid cells from patients with intermittent allergic rhinitis. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2005; 35(4):p.473-8.
5. Lakind JS et al., A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary eff ects. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2007 12(5):p.445-67.
6. Shijubo N et al., Serum and BAL Clara cell 10 kDa protein (CC10) levels and CC10-positive bronchiolar cells are decreased in smokers. The European respiratory journal : offi cial journal of the European Society for Clinical Respiratory Physiology 1997; 10(5):p.1108-14.
7. Hermans C and A Bernard, Lung epithelium-specifi c proteins: characteristics and potential applications as markers. American journal of respiratory and critical care medicine 1999; 159(2):p.646-78.
8. Bernard A et al., Clara cell protein in serum and bronchoalveolar lavage. The European respiratory journal : offi cial journal of the European Society for Clinical Respiratory Physiology 1992; 5(10): p. 1231-8.
9. Pilette C et al., Reduced epithelial expression of secretory component in small airways correlates with airfl ow obstruction in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2001; 163(1):p.185-94.
10. Braido F et al., Clara cell 16 protein in COPD sputum: a marker of small airways damage? Respiratory medicine 2007; 101(10):p.2119-24.
11. Ye Q et al., Serum CC-10 in infl ammatory lung diseases. Respiration; international review of thoracic diseases 2004; 71(5):p.505-10.
12. Sin DD et al., Circulating surfactant protein D as a potential lung-specifi c biomarker of health outcomes in COPD: a pilot study. BMC pulmonary medicine 2007; 7:p.13.
13. Lomas DA et al., Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Th orax 2008; 63(12):p.1058-63.
14. Broeckaert F et al., Clara cell secretory protein (CC16): features as a peripheral lung biomarker. Annals of the New York Academy of Sciences 2000; 923:p.68-77.
15. Hermans C et al., Determinants of serum levels of surfactant proteins A and B and Clara cell protein CC16. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2003; 8(6):p.461-71.
16. Vestbo J et al., Changes in forced expiratory volume in 1 second over time in COPD. The New England journal of medicine 2011; 365(13):p.1184-92.
17. Celli BR et al., Infl ammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine 2012; 185(10):p.1065-1072.
18. Lomas DA et al., An oral inhibitor of p38 MAP kinase reduces plasma fi brinogen in patients with chronic obstructive pulmonary disease. Journal of clinical pharmacology 2012; 52(3):p.416-24.
19. Ge XN et al., Rofl umilast increases Clara cell secretory protein in cigarette smoke-exposed mice. COPD 2009; 6(3):p.185-91.